Business Context and Reporting Period
This Form 8-K, filed on June 7, 2022, reports on the Special Meeting of Stockholders convened by Dynamics Special Purpose Corp. (DYNS). The meeting approved the business combination with Senti Biosciences, Inc., which will result in the combined entity operating as "Senti Biosciences, Inc." (New Senti). The closing of the transaction is expected to occur on or about June 8, 2022.
Key Financial Metrics and Voting Results
This filing is a current report regarding corporate governance and transaction approval; it does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics for the company.
Voting Participation:
- Shares Present: 21,227,566 Class A and 5,750,000 Class B shares.
- Total Outstanding: 23,715,500 Class A and 5,750,000 Class B shares.
Redemption Activity:
- Shares Redeemed: 14,549,537 shares of Class A common stock were validly elected for redemption by public stockholders.
Material Changes and Transaction Approval
Stockholders approved the following key proposals to facilitate the business combination:
- Business Combination (Proposal 1): Approved with 23,617,750 votes "For" and 3,359,816 "Against".
- Charter Amendment (Proposal 2): Approved to amend the certificate of incorporation and bylaws for New Senti.
- Corporate Name Change (Proposal 3A): Approved to change the name to "Senti Biosciences, Inc."
- Authorized Share Increase (Proposal 3B): Approved to increase authorized common stock to 500,000,000 shares.
- Preferred Stock Authorization (Proposal 3C): Approved to authorize up to 10,000,000 shares of preferred stock.
- Board Structure (Proposal 3D): Approved to divide the board into three classes with staggered terms and require a 75% vote for removal of directors.
- Supermajority Voting (Proposal 3E): Approved to require 75% approval for certain charter amendments.
- Perpetual Existence (Proposal 3F): Approved to make corporate existence perpetual and remove SPAC-specific provisions.
- Written Consent Removal (Proposal 3G): Approved to remove the ability of stockholders to act by written consent.
- Nasdaq Listing (Proposal 4): Approved the issuance of up to 26,000,000 shares for the combination and 6,680,000 shares for a concurrent private placement.
- Director Elections (Proposal 5): Seven directors were elected to serve staggered terms.
- Equity Plans (Proposals 6 & 7): Approved the New Senti 2022 Equity Incentive Plan and Employee Stock Purchase Plan (ESPP).
Outlook, Risks, and Contingencies
Closing Contingency: The transaction closing is expected on or about June 8, 2022, subject to the satisfaction or waiver of conditions in the Business Combination Agreement.
Redemption Rights: Public stockholders who elected to redeem their shares may revoke these elections at any time prior to the closing of the Business Combination.
Management Commentary: The filing notes that the adjournment proposal was not presented because sufficient votes were obtained to approve the other proposals.
Investor Verification Checklist
- Verify the final closing date of the Business Combination, currently expected on or about June 8, 2022.
- Confirm the final number of shares redeemed, noting that redemptions can be revoked prior to closing.
- Review the Definitive Proxy Statement (Schedule 14A) filed on May 13, 2022, for full details on the Equity Incentive Plan and ESPP.
- Monitor the issuance of the 26,000,000 shares for the combination and 6,680,000 shares for the private placement to ensure compliance with Nasdaq listing rules.
- Check for any updates regarding the satisfaction of conditions in the Business Combination Agreement.